(S)-1-(4-chlorophenyl)-3-(piperidin-1-yl)propan-1-amine | 1296852-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-(4-chlorophenyl)-3-(piperidin-1-yl)propan-1-amine
• CAS: 1296852-29-3
• 化学式: C₁₄H₂₁ClN₂
• 分子量: 252.787
• InChiKey: NDVLPWRGUJKXCX-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.22
• 重原子数：
  17.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  29.26
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  4-((叔丁氧基羰基)氨基)-1-(7H-吡咯并[2,3-D]嘧啶-4-基)哌啶-4-羧酸 、 (S)-1-(4-chlorophenyl)-3-(piperidin-1-yl)propan-1-amine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙二醇二甲醚 为溶剂， 反应 16.0h， 以17%的产率得到4-amino-N-[(1S)-1-(4-chlorophenyl)-3-piperidin-1-ylpropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
  参考文献：
  名称：

  Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases

  摘要：

  Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.

  DOI：

  10.1021/jm301762v
• 作为产物：
  描述：

  (S)-对氯-Β-苯丙氨醇 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 26.25h， 生成 (S)-1-(4-chlorophenyl)-3-(piperidin-1-yl)propan-1-amine
  参考文献：
  名称：

  Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases

  摘要：

  Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.

  DOI：

  10.1021/jm301762v